Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Exelixis (EXEL)

Exelixis Reports Third Quarter 2026 Total Revenues of $658.7 Million and GAAP Diluted EPS of $0.85

Positive Impact 3 of 5 earnings

Exelixis, Inc. reported its third quarter 2026 financial results, showing an increase in total revenues to $658.7 million compared to $597.8 million for the same period in 2025. GAAP net income rose to $218.1 million, or $0.85 per diluted share, driven by higher net product sales from the cabozantinib franchise.

Key points

  • Total revenues for the quarter ended September 30, 2026, were $658.7 million, up from $597.8 million in the third quarter of 2025.
  • GAAP net income for the third quarter of 2026 was $218.1 million, or $0.85 per diluted share.
  • Cabozantinib franchise U.S. net product revenues reached $604.9 million for the quarter.
  • Exelixis updated its full-year 2026 financial guidance, including total revenues projected between $2.500 billion and $2.550 billion.

The filing

CompanyExelixis (EXEL)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:09 PM ET
Accession number0000939767-26-000114

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Google Gemini, gemini-3.5-flash-lite) on Oct 30, 2026, 4:16 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.